TR200401622T4 - Pürin türevleri - Google Patents

Pürin türevleri

Info

Publication number
TR200401622T4
TR200401622T4 TR2004/01622T TR200401622T TR200401622T4 TR 200401622 T4 TR200401622 T4 TR 200401622T4 TR 2004/01622 T TR2004/01622 T TR 2004/01622T TR 200401622 T TR200401622 T TR 200401622T TR 200401622 T4 TR200401622 T4 TR 200401622T4
Authority
TR
Turkey
Prior art keywords
purine derivatives
compounds
adenosine
solvates
preparing
Prior art date
Application number
TR2004/01622T
Other languages
English (en)
Inventor
John Mantell S�Mon
Marina Monaghan Sandra
Thomas Stephenson Peter
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of TR200401622T4 publication Critical patent/TR200401622T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)

Abstract

Bu bulus formül (I) e sahip bilesikleri ve bunlarin farmasötik açidan kabul edilebilir tuzlari ve solvatlari, bunlari hazirlamak için yöntemler, bunlarin hazirlanmasinda kullanilan ara bilesikler, bunlari ihtiva eden terkipler ve bu gibi bilesiklerin adenosin A2a reseptörü agonistleri olarak kullanimlari ile ilgilidir.
TR2004/01622T 2000-06-27 2001-06-14 Pürin türevleri TR200401622T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0015727.1A GB0015727D0 (en) 2000-06-27 2000-06-27 Purine derivatives

Publications (1)

Publication Number Publication Date
TR200401622T4 true TR200401622T4 (tr) 2004-08-23

Family

ID=9894500

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01622T TR200401622T4 (tr) 2000-06-27 2001-06-14 Pürin türevleri

Country Status (42)

Country Link
EP (1) EP1296996B1 (tr)
JP (1) JP2004501929A (tr)
KR (1) KR20030036248A (tr)
CN (1) CN1432020A (tr)
AP (1) AP1372A (tr)
AR (1) AR028759A1 (tr)
AT (1) ATE267836T1 (tr)
AU (1) AU2001264164A1 (tr)
BG (1) BG107171A (tr)
BR (1) BR0111912A (tr)
CA (1) CA2412564C (tr)
CZ (1) CZ20023992A3 (tr)
DE (1) DE60103537T2 (tr)
DK (1) DK1296996T3 (tr)
DO (1) DOP2001000195A (tr)
EA (1) EA200201291A1 (tr)
EC (1) ECSP024396A (tr)
EE (1) EE200200712A (tr)
ES (1) ES2220775T3 (tr)
GB (1) GB0015727D0 (tr)
GT (1) GT200100119A (tr)
HR (1) HRP20020995A2 (tr)
HU (1) HUP0301389A3 (tr)
IL (1) IL152529A0 (tr)
IS (1) IS6580A (tr)
MA (1) MA26918A1 (tr)
MX (1) MXPA03000078A (tr)
NO (1) NO20025975L (tr)
NZ (1) NZ521867A (tr)
OA (1) OA12294A (tr)
PA (1) PA8521001A1 (tr)
PE (1) PE20020213A1 (tr)
PL (1) PL361384A1 (tr)
PT (1) PT1296996E (tr)
SI (1) SI1296996T1 (tr)
SK (1) SK17332002A3 (tr)
SV (1) SV2002000507A (tr)
TN (1) TNSN01096A1 (tr)
TR (1) TR200401622T4 (tr)
UY (1) UY26797A1 (tr)
WO (1) WO2002000676A1 (tr)
ZA (1) ZA200209557B (tr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE340794T1 (de) 2001-08-14 2006-10-15 Lilly Co Eli Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
AU2005286946B2 (en) * 2004-09-20 2012-03-15 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AU2006303452B2 (en) 2005-10-21 2011-06-09 Novartis Ag Human antibodies against IL13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2322525B1 (en) * 2006-04-21 2013-09-18 Novartis AG Purine derivatives for use as adenosin A2A receptor agonists
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
JP5143953B2 (ja) 2008-06-11 2013-02-13 レーザーゲン インコーポレイテッド ヌクレオチドおよびヌクレオシドならびにｄｎａ配列決定におけるその使用の方法
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
IL107101A0 (en) * 1992-09-30 1993-12-28 Merrell Dow Pharma 2-substituted adenosines with a-2 receptor affinity
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
CA2317093A1 (en) * 1998-01-08 1999-07-15 Joel M. Linden A2a adenosine receptor agonists
WO2000023457A1 (en) * 1998-10-16 2000-04-27 Pfizer Limited Adenine derivatives
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
EP1296996A1 (en) 2003-04-02
UY26797A1 (es) 2002-01-31
IS6580A (is) 2002-10-10
CA2412564A1 (en) 2002-01-03
PE20020213A1 (es) 2002-03-19
DOP2001000195A (es) 2002-05-15
DE60103537T2 (de) 2005-07-07
EA200201291A1 (ru) 2003-04-24
GB0015727D0 (en) 2000-08-16
NO20025975D0 (no) 2002-12-12
SI1296996T1 (en) 2004-10-31
HUP0301389A2 (hu) 2003-08-28
MXPA03000078A (es) 2003-08-19
CA2412564C (en) 2007-10-02
ZA200209557B (en) 2003-12-02
PT1296996E (pt) 2004-08-31
SV2002000507A (es) 2002-07-03
HRP20020995A2 (en) 2005-02-28
IL152529A0 (en) 2003-05-29
ES2220775T3 (es) 2004-12-16
SK17332002A3 (sk) 2004-03-02
PA8521001A1 (es) 2002-04-25
EP1296996B1 (en) 2004-05-26
AP1372A (en) 2005-02-21
KR20030036248A (ko) 2003-05-09
HUP0301389A3 (en) 2005-02-28
GT200100119A (es) 2002-01-31
EE200200712A (et) 2004-06-15
CZ20023992A3 (cs) 2003-12-17
OA12294A (en) 2003-11-14
ATE267836T1 (de) 2004-06-15
NZ521867A (en) 2004-04-30
JP2004501929A (ja) 2004-01-22
NO20025975L (no) 2002-12-12
TNSN01096A1 (fr) 2005-11-10
DK1296996T3 (da) 2004-08-16
BR0111912A (pt) 2003-05-13
AU2001264164A1 (en) 2002-01-08
ECSP024396A (es) 2003-02-06
WO2002000676A1 (en) 2002-01-03
AR028759A1 (es) 2003-05-21
DE60103537D1 (de) 2004-07-01
BG107171A (en) 2003-07-31
PL361384A1 (en) 2004-10-04
MA26918A1 (fr) 2004-12-20
CN1432020A (zh) 2003-07-23

Similar Documents

Publication Publication Date Title
TR200401622T4 (tr) Pürin türevleri
TR200201001T2 (tr) Pürin türevleri
TR200200985T2 (tr) Pürin türevleri
TR200103607T2 (tr) Pürin Türevleri
AP2002002598A0 (en) Purine derivatives.
AP2001002287A0 (en) Purine derivatives.
ATE331726T1 (de) Adenine-derivate
UY26398A1 (es) Derivados de purina